Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes

What Was Tested

The paper reports a study of Exenatide, published as a randomized controlled trial.

Endothelial dysfunction is frequently present in individuals with insulin resistance or type 2 diabetes and can be induced by high-fat or high-carbohydrate meals.

Who Took Part

According to the abstract, 28 individuals were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

Neither the individuals nor the staff measuring them knew who was on Exenatide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.

Each person switched between Exenatide and the comparison at some point, usually with a gap in between.

In a double-blinded randomized crossover design, postprandial endothelial function was examined in 28 individuals with impaired glucose tolerance or recent-onset type 2 diabetes after a single injection of exenatide or placebo given just before a high-fat meal.

Endothelial function was determined with peripheral arterial tonometry pre- and postprandially.

What Was Measured

Topics PubMed links to this paper include Age of Onset, Cohort Studies, Diabetes Mellitus, Type 2, Dietary Fats, Endothelium, Exenatide and Glucose Intolerance.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide in 28 individuals.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (Diabetes care), a journal based in United States.

More context: the Exenatide compound page, all human trials.